{"ticker": {"uuid": "ccdf6548-2eeb-48d2-a37a-8b3a542c0ba5", "symbol": "EGTX", "name": "Egetis Therapeutics AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Egetis Therapeutics AB submits rolling NDA for tiratricol", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQks5OVhYc0UxZEdacVVldzhGNjlVYmhzYUdCdE83X0xSWndKZWJwLTVscjJ3eHdYTkdXU1RMcXVYRTdqc2pGaUlpcnRpLXpQSm8tQUFVZjJSajdYbWotSHEyckJWMjVPTXhwQ0dqenpKTGh3YnV4ZEc0ZVhaRVlUblhld2REUFFkckljbUVVMDRmQVptUVpoRmRzSHlZajFxNzR3REZ5ckc?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Egetis Eager To Launch Ultra Rare Disease Drug Emcitate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxObmZ0WE11T0NITDVoaXVMYWxpcnBLcVpwcnU4dlZXOWY4T09WZmFDalpOcXVRU3l5YmFHRll1WlBkQWxlOThkOUdpcm9xM1g3UllIR3hySWxIS3NCZVkxN3BPdXVTNk5ZT3NqS0YwTzFsem82TE1ITkRENTdVLWxJbHNMRDFERldqSkFZT3Q2TVViZ3h4dkprcUlib0Y0UmVqY0VZWVFFbE1WLWpRakliaTA3cmJJN3lEMlRVam96dl9CTnIyWDVDdTR1TjJXZ2tiZWVHTw?oc=5", "source_name": "insights.citeline.com", "published_at": "2025-02-14T08:00:00+00:00", "published_display": "14 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EGETIS THERAPEUTICS AB (PDPHF) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9jNmVQc3Fja3RSTkpLLWljM2d2V1BWQXR1Snc5R3lGQjNneHNrRGZaXzFkWVV1anJxM1NadDhzVklSWTBiYUsydURQaWFlRENHRmxTZzQydWZscW5ZYkxjbWxqYmpOVGs?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akiram Therapeutics strengthens board with drug development expertise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQTC1TUXBsOTNtZE11NVM2NHZZS3FWZjB3SW5kTlFES0I5SkllSVIteDZ0aTFFbTh2dF9UX0h5LThFdmVqN0F0bjI0QjBOakxzSkJnZ2hwUDNQN1czOWR5enNvTkN2WER2aGJsOHRQVW5zMEw3UkV0Y0dIa2EzQXZxTUpwNWpNS2M2clFTZGJXMTZ2VkFZbGZtak9FTXJRTElfTjVsT2ZfNE9xbUwzUnNSaWFMM1Z5ODlFWWI5cHZvSk1RQQ?oc=5", "source_name": "Cision News", "published_at": "2023-12-19T08:00:00+00:00", "published_display": "19 Dec 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Egetis Therapeutics AB submits rolling NDA for tiratricol", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNQks5OVhYc0UxZEdacVVldzhGNjlVYmhzYUdCdE83X0xSWndKZWJwLTVscjJ3eHdYTkdXU1RMcXVYRTdqc2pGaUlpcnRpLXpQSm8tQUFVZjJSajdYbWotSHEyckJWMjVPTXhwQ0dqenpKTGh3YnV4ZEc0ZVhaRVlUblhld2REUFFkckljbUVVMDRmQVptUVpoRmRzSHlZajFxNzR3REZ5ckc?oc=5", "source_name": "European Biotechnology Magazine", "published_at": "2025-12-19T08:00:00+00:00", "published_display": "19 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Egetis Eager To Launch Ultra Rare Disease Drug Emcitate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxObmZ0WE11T0NITDVoaXVMYWxpcnBLcVpwcnU4dlZXOWY4T09WZmFDalpOcXVRU3l5YmFHRll1WlBkQWxlOThkOUdpcm9xM1g3UllIR3hySWxIS3NCZVkxN3BPdXVTNk5ZT3NqS0YwTzFsem82TE1ITkRENTdVLWxJbHNMRDFERldqSkFZT3Q2TVViZ3h4dkprcUlib0Y0UmVqY0VZWVFFbE1WLWpRakliaTA3cmJJN3lEMlRVam96dl9CTnIyWDVDdTR1TjJXZ2tiZWVHTw?oc=5", "source_name": "insights.citeline.com", "published_at": "2025-02-14T08:00:00+00:00", "published_display": "14 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EGETIS THERAPEUTICS AB (PDPHF) Revenue Breakdown - Main Composition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9jNmVQc3Fja3RSTkpLLWljM2d2V1BWQXR1Snc5R3lGQjNneHNrRGZaXzFkWVV1anJxM1NadDhzVklSWTBiYUsydURQaWFlRENHRmxTZzQydWZscW5ZYkxjbWxqYmpOVGs?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akiram Therapeutics strengthens board with drug development expertise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQTC1TUXBsOTNtZE11NVM2NHZZS3FWZjB3SW5kTlFES0I5SkllSVIteDZ0aTFFbTh2dF9UX0h5LThFdmVqN0F0bjI0QjBOakxzSkJnZ2hwUDNQN1czOWR5enNvTkN2WER2aGJsOHRQVW5zMEw3UkV0Y0dIa2EzQXZxTUpwNWpNS2M2clFTZGJXMTZ2VkFZbGZtak9FTXJRTElfTjVsT2ZfNE9xbUwzUnNSaWFMM1Z5ODlFWWI5cHZvSk1RQQ?oc=5", "source_name": "Cision News", "published_at": "2023-12-19T08:00:00+00:00", "published_display": "19 Dec 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 63, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 6.08, "latest_week": "2026-07-10", "one_week_move": 5.7, "four_week_move": 14.1, "twelve_week_move": 14.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.449813, "market_dynamics_buy_signal": false, "relative_strength": 0.907368, "fair_value_gap": 13.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.6517, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.7% over one week, +14.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "European Biotechnology Magazine", "count": 1}, {"label": "insights.citeline.com", "count": 1}, {"label": "Moomoo", "count": 1}, {"label": "Cision News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+5.7% over one week, +14.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Egetis Therapeutics AB submits rolling NDA for tiratricol"}], "updated_at": "2026-07-17T18:57:51.621429+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}